Update on antiretroviral agents other than zidovudine

Affiliations

Review

R P Johnson et al. AIDS. 1989.

. 1989:3 Suppl 1:S145-51.

doi: 10.1097/00002030-198901001-00022.

No abstract available

Similar articles

[The AIDS virus: strategies for attacking it].
Carrasco L. Carrasco L. Enferm Infecc Microbiol Clin. 1995 Nov;13(9):540-9. Enferm Infecc Microbiol Clin. 1995. PMID: 8519837 Review. Spanish. No abstract available.
In search of specific inhibitors of retrovirus replication.
De Clercq E, Balzarini J. De Clercq E, et al. Antiviral Res. 1985;Suppl 1:89-94. doi: 10.1016/s0166-3542(85)80013-9. Antiviral Res. 1985. PMID: 2417552 No abstract available.
How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors.
De Clercq E. De Clercq E. AIDS. 1994 Jul;8(7):1020-1. doi: 10.1097/00002030-199407000-00028. AIDS. 1994. PMID: 7524543 No abstract available.
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR. Campbell TB, et al. J Infect Dis. 1993 Aug;168(2):318-26. doi: 10.1093/infdis/168.2.318. J Infect Dis. 1993. PMID: 7687641
Spectrum of antiviral activity and mechanism of action of zidovudine. An overview.
Furman PA, Barry DW. Furman PA, et al. Am J Med. 1988 Aug 29;85(2A):176-81. Am J Med. 1988. PMID: 3044082 Review.

Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).
Whittington R, Brogden RN. Whittington R, et al. Drugs. 1992 Oct;44(4):656-83. doi: 10.2165/00003495-199244040-00009. Drugs. 1992. PMID: 1281077 Review.